237 related articles for article (PubMed ID: 28684771)
1. The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
Appel CK; Gallego-Pedersen S; Andersen L; Blancheflor Kristensen S; Ding M; Falk S; Sayilekshmy M; Gabel-Jensen C; Heegaard AM
Sci Rep; 2017 Jul; 7(1):4792. PubMed ID: 28684771
[TBL] [Abstract][Full Text] [Related]
2. Effects of Src-kinase inhibition in cancer-induced bone pain.
De Felice M; Lambert D; Holen I; Escott KJ; Andrew D
Mol Pain; 2016; 12():. PubMed ID: 27094550
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
4. A rat model of bone cancer pain.
Medhurst SJ; Walker K; Bowes M; Kidd BL; Glatt M; Muller M; Hattenberger M; Vaxelaire J; O'Reilly T; Wotherspoon G; Winter J; Green J; Urban L
Pain; 2002 Mar; 96(1-2):129-40. PubMed ID: 11932069
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.
Araujo JC; Poblenz A; Corn P; Parikh NU; Starbuck MW; Thompson JT; Lee F; Logothetis CJ; Darnay BG
Cancer Biol Ther; 2009 Nov; 8(22):2153-9. PubMed ID: 19855158
[TBL] [Abstract][Full Text] [Related]
6. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Karim SA; Creedon H; Patel H; Carragher NO; Morton JP; Muller WJ; Evans TR; Gusterson B; Sansom OJ; Brunton VG
J Pathol; 2013 Aug; 230(4):430-40. PubMed ID: 23616343
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.
Vandyke K; Dewar AL; Diamond P; Fitter S; Schultz CG; Sims NA; Zannettino AC
J Bone Miner Res; 2010 Aug; 25(8):1759-70. PubMed ID: 20225261
[TBL] [Abstract][Full Text] [Related]
9. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
10. Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Ortiz R; Díaz J; Díaz-Valdivia N; Martínez S; Simón L; Contreras P; Lobos-González L; Guerrero S; Leyton L; Quest AFG
Biochem Pharmacol; 2020 Jul; 177():113941. PubMed ID: 32240650
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
12. The multi-kinase inhibitor dasatinib suppresses autoinflammation and increases bone density in a mouse model for chronic recurrent multifocal osteomyelitis.
Yoshikawa R; Abe K
Cell Biochem Funct; 2021 Jun; 39(4):521-527. PubMed ID: 33527496
[TBL] [Abstract][Full Text] [Related]
13. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
16. Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain.
Yoneda T; Hiasa M; Nagata Y; Okui T; White F
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2677-84. PubMed ID: 25687976
[TBL] [Abstract][Full Text] [Related]
17. Arcuate Src activation-induced phosphorylation of NR2B NMDA subunit contributes to inflammatory pain in rats.
Xu L; Pan Y; Zhu Q; Gong S; Tao J; Xu GY; Jiang X
J Neurophysiol; 2012 Dec; 108(11):3024-33. PubMed ID: 22993256
[TBL] [Abstract][Full Text] [Related]
18. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
[TBL] [Abstract][Full Text] [Related]
19. [The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells].
Wang Z; Li L; Shao Z; Xie H; Yang F; Zhou N
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 May; 32(5):595-9. PubMed ID: 27126935
[TBL] [Abstract][Full Text] [Related]
20. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]